Impact Biomedical Inc（IBO）财务数据IBOImpact Biomedical Inc

Evaluating the bottom line, Impact Biomedical Inc maintains a gross margin of -9400.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 28487.50%, while the net margin is 28425.00%. These profitability ratios, combined with a Return on Equity (ROE) of 433.42%, provide a clear picture of how effectively IBO converts its operational activities into shareholder value.

In the context of the broader market, IBO competes directly with industry leaders such as ACFN and FEMY. With a market capitalization of $49.38M, it holds a significant position in the sector. When comparing efficiency, IBO's gross margin of -9400.00% stands against ACFN's 82.36% and FEMY's 32.12%. Such benchmarking helps identify whether Impact Biomedical Inc is trading at a premium or discount relative to its financial performance.

The company reported a net income of -14,746,000 USD in Q2 2025 and has shown inconsistent revenue growth, with total revenue fluctuating between 0 and 18,000 USD over the past quarters.